Iclusig Dosage

Generic name: ponatinib
Drug classes: BCR-ABL tyrosine kinase inhibitors, Multikinase inhibitors, VEGF/VEGFR inhibitors

Medically reviewed by  A Ras MD.

Recommended Adult Dosing

Dosage forms:  TAB: 10 mg, 15 mg, 30 mg, 45 mg

CML

[chronic phase]

Dose: 10-45 mg PO qd; Start: 45 mg PO qd; Info: for pts w/ T315I-positive dz or for pts w/ dz resistant or intolerant to at least 2 kinase inhibitors; decr. dose to 15 mg PO qd if 1% or less BCR-ABL1 achieved; consider D/C tx if hematologic response not achieved by 3mo; do not cut/crush/chew tab

[accelerated phase]

Dose: 15-45 mg PO qd; Start: 45 mg PO qd; Info: for pts w/ T315I-positive dz or for pts whom no other kinase inhibitors are indicated; consider decr. dose if major cytogenetic response achieved; consider D/C tx if response not achieved by 3mo; do not cut/crush/chew tab

[blast phase]

Dose: 15-45 mg PO qd; Start: 45 mg PO qd; Info: for pts w/ T315I-positive dz or for pts whom no other kinase inhibitors are indicated; consider D/C tx if response not achieved by 3mo; do not cut/crush/chew tab

Ph-positive ALL

[15-45 mg PO qd]

Start: 45 mg PO qd; Info: for pts w/ T315I-positive dz or for pts whom no other kinase inhibitors are indicated; consider D/C tx if response not achieved by 3mo; do not cut/crush/chew tab

Renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

Hepatic dosing

[adjust dose amount]

Child-Pugh Class A, B or C: start 30 mg qd

SRC: NLM .